Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL)
· seekingalpha.com
Replimune Group, Inc. downgraded to Sell ahead of FDA Adcom on RP1+Opdivo in melanoma. Click for this REPL update.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...